Skip to content

All best practices

CS-140success

Hikma Pharmaceuticals PLC (established in Amman, Jordan, in 1978; listed in London from 2005)

London listing and acquisition-led expansion across the Middle East and North Africa, Europe and the US generic injectables market (2005-2011)

Region
Middle East, Africa, North America
Country
Jordan, United Kingdom, United States, Egypt, Algeria, Morocco
Industry
Pharmaceuticals and Life Sciences (Chemicals and Process Manufacturing)
Functions
Strategy, Corporate Development & Transformation Office, Finance & FP&A, Marketing & Go-to-Market, Manufacturing & Production, Product, R&D & Innovation
Topics
Revenue growth has stalled; Investment capital is not generating returns; M&A integration or corporate complexity is destroying value
Starting situation
New initiative
Period
2005–2011
Last verified
4 November 2026

Executive summary

Hikma was a family-run Jordanian drug maker with revenue of US$214m in 2004, a US subsidiary (West-Ward) and FDA-inspected plants in the region and in Portugal [C01, C03, C05]. In 2005 it listed in London, raising US$124m, with the stated aims of reaching international investors and growing by acquisition in the Middle East and North Africa [C02, C06, C07].

Over the next six years it bought companies in Egypt, Jordan, Germany, Tunisia, Algeria and Morocco and, in 2011, Baxter's US generic injectables business, which doubled its injectables sales and made it the second-largest US supplier by volume [C10, C12, C14, C18, C20].

Revenue rose from US$262.2m in 2005 to US$918.0m in 2011 [C08, C20]. The lesson for a CEO of a mid-sized company: a listing works as a transformation tool when it funds a stated acquisition plan, and when the company spreads itself across segments and regions so that one setback does not stop the plan.

Outcome: success

The stated objectives were reported met, and the outcome was not later reversed by a write-down, exit or abandonment attributable to the initiative.

Basis of the outcome

When it listed in London in 2005, Hikma's stated aims were access to international investors and growth by acquisition in the Middle East and North Africa (S02, S03, S07). It raised US$124m at listing (S05), then bought companies in Egypt, Jordan, Germany, Tunisia, Algeria and Morocco and Baxter's US generic injectables business (S09, S10, S11, S14, S16); revenue rose from US$262.2m in 2005 to US$918.0m in 2011 and the Baxter deal made it the second-largest US supplier of generic injectables by volume (S03, S16). The stated aims were reported met and no write-down or exit attributable to the programme was found in the period, which meets the success criterion.

Key figures

PhaseFigureValueWhenVerification
BeforeNet salesUS$214.1m2004press_reported
BeforeValuation at listing (midpoint)about £500mOct 2005multiple_independent
DuringGross listing proceedsUS$124m2005company_reported
DuringAcquisitions in 2007about US$300m2007multiple_independent
DuringBaxter injectables purchaseabout US$112m2010-2011multiple_independent
AfterRevenueUS$918.0m2011company_reported
AfterProfit attributableUS$80.1m2011company_reported
AfterUS share of revenue34.6%2011company_reported
press_reported
A journalist's own reporting.
multiple_independent
Two or more independent sources agree.
company_reported
A company statement, press release or investor presentation that no one has independently checked.

Sources

  1. S01 Hikma Pharmaceuticals says plans London IPO · Reuters, BioSpace (Reuters), 2005-10-19 · accessed 2026-11-04
  2. S02 Hikma plans to float on LSE next month · City A.M. Reporter, City A.M., 2005-10-18 · accessed 2026-11-04
  3. S03 Hikma Preliminary Results (year ended 31 December 2005) · Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals PLC (RNS via Investegate), 2006-03-29 · accessed 2026-11-04
  4. S04 Hikma sees revenue growth of 23.5% in 2005 · not stated, The Pharma Letter, 2006 · accessed 2026-11-04
  5. S05 Our history · Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals PLC, not stated · accessed 2026-11-04
  6. S06 Hikma Pharmaceuticals (member profile) · not stated, American Chamber of Commerce in Jordan, not stated · accessed 2026-11-04
  7. S07 Growth in Jordan's pharmaceuticals: a Hikma case study · not stated, Wamda (with the El Khazindar Business Research and Case Center, American University in Cairo), 2013-10-20 · accessed 2026-11-04
  8. S08 Hikma Pharmaceuticals revenues increase 41.6% · Staff Writer, Emirates 24|7, 2008-03-19 · accessed 2026-11-04
  9. S09 Hikma's full-year 2007 revenue jumps 41.6% · not stated, The Pharma Letter, 2008-03-30 · accessed 2026-11-04
  10. S10 Hikma Pharmaceuticals PLC: Final results for the year ended 31 December 2008 · Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals PLC (RNS via LSE.co.uk), 2009-03-17 · accessed 2026-11-04
  11. S11 Hikma Pharmaceuticals PLC: Preliminary results for the year ended 31 December 2010 · Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals PLC (RNS via LSE.co.uk), 2011-03-16 · accessed 2026-11-04
  12. S12 Hikma builds in US injectables sector with Baxter unit buy · Gareth Macdonald, Outsourcing-Pharma, 2010-11-02 · accessed 2026-11-04
  13. S13 Hikma buying into the US market · not stated, GaBI Online, 2011-04-08 · accessed 2026-11-04
  14. S14 Hikma Pharmaceuticals Completes the Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business · Hikma Pharmaceuticals PLC, BioSpace (company release), 2011-05-03 · accessed 2026-11-04
  15. S15 Hikma full year 2010 results: interview with Said Darwazah, CEO · not stated, Stockopedia, 2011 · accessed 2026-11-04
  16. S16 Hikma Pharmaceuticals PLC: Preliminary results for the year ended 31 December 2011 · Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals PLC (RNS via LSE.co.uk), 2012-03-14 · accessed 2026-11-04

Researched and fact-checked knowledgebase · Knowledgebase built 5 November 2026 · Last verified 4 November 2026

Practices, their evidence grades and case summaries are public. Full case studies are available in AXIOM to subscribers and AXIOM Discover participants.